LRRK2 G2385R Leucocyte and Urine Biomarker Study

Identifying Leucocyte and Urine Biomarkers in Parkinson's Patients With LRRK2 G2385R Gene Variant

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04436848

Acronym

LRRK2 G2385R

Enrollment

150

Registered

2020-06-18

Start date

2020-06-01

Completion date

2022-06-30

Last updated

2020-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

Given the emerging evidence on LRRK2-related biomarkers, this project will focus on identifying leucocyte and urine biomarkers that are altered by the LRRK2 G2385R variant, and investigating the effects of LRRK2 kinase inhibitor (MLi-2) on these biomarkers, using immunoblotting and mass spectrometry.

Interventions

OTHERThis is a non-interventional study

This is a non-interventional study

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Diagnosis of Parkinson's disease assigned by a movement disorder specialist according to clinical diagnostic criteria * Age above 18 year-old * Provision of a written informed consent

Exclusion criteria

\- Physical or mental incapacity to complete study protocol

Design outcomes

Primary

Measure	Time frame
Identification of monocyte-based biomarkers for LRRK2 G2385R variant	Two years
Identification of urine-based biomarkers for LRRK2 G2385R variant	Two years

Countries

Malaysia

Contacts

Primary ContactAi Huey Tan, MD, FRCP

aihuey.tan@gmail.com60379492891

Backup ContactShen Yang Lim, MD, FRACP

limshenyang@gmail.com60379492891

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026